Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin in pediatric relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma
NL-OMON37406Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Oct 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), sponsored by Takeda. Primary endpoints: Safety, Pharmacokinetics and 1 more. Started Oct 2012; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NL-OMON37406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37406.